Cedars-Sinai Medical Center

medical staff pulse newsletter

Text size: A A A
A BI-WEEKLY PUBLICATION FROM THE CEDARS-SINAI CHIEF OF STAFF May 23, 2014 | Archived Issues

Meetings and Events


Grand Rounds

Click here to view upcoming grand rounds.


Upcoming CME Conferences

Click below to view a complete list of all scheduled Continuing Medical Education conferences.

CME Newsletter - May 2014


Milestones

Do you know of a significant event in the life of a medical staff member? Please let us know, and we'll post these milestones in Medical Staff Pulse. Also, feel free to submit comments on milestones, and we'll post the comments in the next issue. Click here to email us your milestones and comments.

» Read more

Share Your News

Won any awards or had an article accepted for publication? Share your news about professional achievements and other items of interest.

Click here to share your news

FDA Compares Blood Thinners, Airs Lunesta Risk

Pharmacy Focus

The U.S. Food and Drug Administration recently completed a study in Medicare patients comparing Pradaxa® (dabigatran) to warfarin for risk of ischemic or clot-related stroke, bleeding in the brain, major gastrointestinal bleeding, myocardial infarction (MI) and death.

The new study included information from more than 134,000 Medicare patients 65 or older, and found that among new users of blood-thinning drugs, Pradaxa was associated with a lower risk than warfarin of clot-related strokes, bleeding in the brain and death.

The study also found an increased risk of major gastrointestinal bleeding with use of Pradaxa as compared to warfarin. The MI risk was similar for the two drugs.

For more information, click here.

Lunesta® Can Impair Next-Day Alertness, FDA Warns

The FDA has notified health professionals and their medical care organizations that the insomnia drug Lunesta (eszopiclone) can cause next-day impairment of driving and other activities that require alertness.

The agency recommends decreasing the starting dose of Lunesta to 1 mg at bedtime.

The FDA approved changes to the Lunesta prescribing information and the patient medication guide to include these new recommendations. The drug labels for generic eszopiclone products also will be updated.

For more information, click here.